Gilead Sciences EBIT 2010-2025 | GILD

Gilead Sciences EBIT for the quarter ending March 31, 2025 was $2.237B, a 151.76% decline year-over-year.

  • Gilead Sciences 2024 EBIT was 1.662B, a 78.15% decline from 2023.
  • Gilead Sciences 2023 EBIT was 7.605B, a 3.75% increase from 2022.
  • Gilead Sciences 2022 EBIT was 7.33B, a 26.09% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

Gilead Sciences EBIT 2010-2025 | GILD

  • Gilead Sciences 2024 EBIT was 1.662B, a 78.15% decline from 2023.
  • Gilead Sciences 2023 EBIT was 7.605B, a 3.75% increase from 2022.
  • Gilead Sciences 2022 EBIT was 7.33B, a 26.09% decline from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Vertex Pharmaceuticals (VRTX)$118.1B
Bristol Myers Squibb (BMY)$96.4B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B
Regencell Bioscience Holdings (RGC)$7.2B